SCHEMBL18822677

SCHEMBL18822677

NCC(=O)OCCOC(=O)CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 14/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ MAPT P10636 4/20 0.34
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ APAF1 O14727 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CYP1A1 P04798 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17345436 0.92 STAT3 (0.51) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345498 0.88 STAT3 (0.56) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL18731231 0.88 STAT3 (0.52) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345513 0.88 STAT3 (0.59) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL18730823 0.88 STAT3 (0.56) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345568 0.88 STAT3 (0.55) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345431 0.88 STAT3 (0.47) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345471 0.87 STAT3 (0.52) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL17345495 0.87 STAT3 (0.49) STAT3ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL21250130 0.87 STAT3 (0.46) STAT3ALDH1A1MAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121299-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 STAT3 1231/4885ALDH1A1 187/4885MAPT 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback